557 related articles for article (PubMed ID: 29721106)
1. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
Reis H; Krafft U; Niedworok C; Módos O; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirady P; Szarvas T
Dis Markers; 2018; 2018():7308168. PubMed ID: 29721106
[TBL] [Abstract][Full Text] [Related]
2. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract][Full Text] [Related]
3. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
4. A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer.
Neumann JM; Niehaus K; Neumann N; Knobloch HC; Bremmer F; Krafft U; Kellner U; Nyirády P; Szarvas T; Bednarz H; Reis H
Lab Invest; 2021 Sep; 101(9):1281-1288. PubMed ID: 34021261
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of APC and PTEN Alterations in Urachal Cancer.
Nagy N; Reis H; Hadaschik B; Niedworok C; Módos O; Szendrői A; Bíró K; Hager T; Herold T; Ablat J; Black PC; Okon K; Tolkach Y; Csizmarik A; Oláh C; Keresztes D; Bremmer F; Gaisa NT; Kriegsmann J; Kovalszky I; Kiss A; Tímár J; Szász MA; Rink M; Fisch M; Nyirády P; Szarvas T
Pathol Oncol Res; 2020 Oct; 26(4):2773-2781. PubMed ID: 32754865
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
[TBL] [Abstract][Full Text] [Related]
7. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
Riva G; Mian C; Luchini C; Girolami I; Ghimenton C; Cima L; Novelli L; Hanspeter E; Mazzoleni G; Schwienbacher C; Pycha S; D'Elia C; Trenti E; Pycha A; Martignoni G; Hes O; Eccher A; Nesi G; Brunelli M
Virchows Arch; 2019 Jan; 474(1):13-20. PubMed ID: 30302546
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls.
Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE
Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312
[TBL] [Abstract][Full Text] [Related]
9. Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
Ke C; Hu Z; Yang C
Cancer Med; 2023 Apr; 12(8):9106-9115. PubMed ID: 36734315
[TBL] [Abstract][Full Text] [Related]
10. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases.
Szarvas T; Módos O; Niedworok C; Reis H; Szendröi A; Szász MA; Nyirády P
Urol Oncol; 2016 Sep; 34(9):388-98. PubMed ID: 27267737
[TBL] [Abstract][Full Text] [Related]
11. [Urachal Cancer: an update of current molecular findings].
Reis H; Mairinger F; Ting S; Nagy N; Witzke KE; Kohl M; Sitek B; Niedworok C; Hadaschik B; Nyirády P; Szarvas T
Pathologe; 2019 Dec; 40(Suppl 3):239-243. PubMed ID: 31705235
[TBL] [Abstract][Full Text] [Related]
12. Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas.
Zhou YW; Long YX; Song K; Liang LB; Cheng K; Chen Y; Liu JY
Cancer Med; 2021 Aug; 10(16):5415-5428. PubMed ID: 34278741
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
[TBL] [Abstract][Full Text] [Related]
14. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O
Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749
[TBL] [Abstract][Full Text] [Related]
15. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
Olah C; Kubik A; Mátrai P; Engh MA; Barna V; Hegyi P; Reis H; Nyirády P; Szarvas T
Urol Oncol; 2024 Jul; 42(7):221.e1-221.e7. PubMed ID: 38627107
[TBL] [Abstract][Full Text] [Related]
17. Value of MRI in evaluating urachal carcinoma: A single center retrospective study.
Das JP; Woo S; Ghafoor S; Andrieu PIC; Ulaner GA; Donahue TF; Goh AC; Vargas HA
Urol Oncol; 2022 Jul; 40(7):345.e9-345.e17. PubMed ID: 35351368
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder.
Raspollini MR; Nesi G; Baroni G; Girardi LR; Taddei GL
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):358-62. PubMed ID: 16280666
[TBL] [Abstract][Full Text] [Related]
19. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
[TBL] [Abstract][Full Text] [Related]
20. Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma.
Zheng Y; Peng H; Hu X; Ou Y; Wang D; Wang H; Ren S
Front Pharmacol; 2023; 14():1199395. PubMed ID: 37324454
[No Abstract] [Full Text] [Related]
[Next] [New Search]
